Table 1.
Patient characteristics by treatment group
| Characteristics | Total (n = 521) | EC-wP (n = 261) | EP-wP (n = 260) |
|---|---|---|---|
| No. (%) | No. (%) | No. (%) | |
| Median age (interquartile range), y | 35 (31-38) | 35 (32-38) | 35 (31-37) |
| Age, y | |||
| ≤35 | 284 (54.5) | 145 (55.6) | 139 (53.5) |
| >35 | 237 (45.5) | 116 (44.4) | 121 (46.5) |
| Pathologic tumor size | |||
| pT1 | 231 (44.3) | 115 (44.1) | 116 (44.6) |
| pT2-3 | 290 (55.7) | 146 (55.9) | 144 (55.4) |
| Pathologic node status | |||
| Negative | 216 (41.5) | 110 (42.1) | 106 (40.8) |
| Positive | 305 (58.5) | 151 (57.9) | 154 (59.2) |
| Histological grade | |||
| I-II | 279 (53.6) | 143 (54.8) | 136 (52.3) |
| III | 242 (46.4) | 118 (45.2) | 124 (47.7) |
| Surgery | |||
| BCS | 168 (32.2) | 83 (31.8) | 85 (32.7) |
| Mastectomy | 353 (67.8) | 178 (68.2) | 175 (67.3) |
| Adjuvant radiation | |||
| No | 212 (40.7) | 109 (41.8) | 103 (39.6) |
| Yes | 309 (59.3) | 152 (58.2) | 157 (60.4) |
| Adjuvant endocrine therapy | |||
| Tamoxifen | 409 (78.5) | 200 (76.7) | 209 (80.4) |
| LHRHa + tamoxifena | 62 (11.9) | 33 (12.6) | 29 (11.2) |
| LHRHa + aromatase inhibitor | 27 (5.2) | 16 (6.1) | 11 (4.2) |
| LHRHa alone | 15 (2.9) | 7 (2.7) | 8 (3.1) |
| No endocrine treatment | 8 (1.5) | 5 (1.9) | 3 (1.1) |
a
Included LHRHa + tamoxifen followed by an aromatase inhibitor. BCS = breast conservative surgery; EC-wP = epirubicin/cyclophosphamide followed by weekly paclitaxel; EP-wP = epirubicin/paclitaxel followed by weekly paclitaxel; LHRHa = luteinizing hormone–releasing hormone agonist.